New chemo combo aims to help laryngeal cancer patients keep their voice
NCT ID NCT03340896
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests whether giving a three-drug chemotherapy regimen (docetaxel, cisplatin, and fluorouracil) before radiotherapy helps people with advanced laryngeal or hypopharyngeal cancer avoid losing their voice box. The standard approach is to give cisplatin during radiotherapy. The study enrolled 256 patients and tracks how many are alive without needing a laryngectomy or tracheostomy two years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Docetaxel, cisplatin, and fluorouracil (chemotherapy drugs)
What this could lead to
If successful, this could show that a specific combination of chemotherapy and radiotherapy helps more people with advanced laryngeal cancer keep their voice box and avoid a laryngectomy.
What could go wrong
This is a Phase 3 trial, but results are not yet reported. The treatments involve strong chemotherapy with significant side effects, and there is no guarantee that the experimental arm will be better than the standard approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Jean Bernard
Le Mans, 72000, France